Mechanism of baricitinib supports artificial intelligence‐predicted testing in COVID‐19 patients

Mechanism of baricitinib supports artificial intelligence‐predicted testing in COVID‐19 patients

Abstract Baricitinib is an oral Janus kinase (JAK)1/JAK2 inhibitor approved for the treatment of rheumatoid arthritis (RA) that was independently predicted, using artificial intelligence (AI) algorithms, to be useful for COVID‐19 infection via proposed anti‐cytokine effects and as an inhibitor of ho...

Full description

Bibliographic Details
Main Authors: Justin Stebbing, Venkatesh Krishnan, Stephanie deBono, Silvia Ottaviani, Giacomo Casalini, Peter J Richardson, Vanessa Monteil, Volker M Lauschke, Ali Mirazimi, Sonia Youhanna, Yee‐Joo Tan, Fausto Baldanti, Antonella Sarasini, Jorge A Ross Terres, Brian J Nickoloff, Richard E Higgs, Guilherme Rocha, Nicole L Byers, Douglas E Schlichting, Ajay Nirula, Anabela Cardoso, Mario Corbellino, the Sacco Baricitinib Study Group
Format: Article
Language:English
Published: Wiley 2020-08-01
Series:EMBO Molecular Medicine
Subjects:
anti‐cytokine
anti‐viral
baricitinib
case series
COVID‐19
Online Access:https://doi.org/10.15252/emmm.202012697

Internet

https://doi.org/10.15252/emmm.202012697

Similar Items